Close
Achema middle east
swop processing & packaging

Future-proof vial filling – How flexibility Along the Line Defines Success

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

IoT-Enabled Packaging for Cold Chain Monitoring

IoT-Enabled Packaging Enhancing Cold Chain Monitoring The pharmaceutical industry has...

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Vial fill-finish operations are changing faster than ever. New regulations such as the revised Annex 1 demand higher automation and less manual intervention, while new products – from large-scale vaccines to small-batch biologics – require significantly more flexible filling equipment and processes. Pharmaceutical manufacturers and CDMOs who want to remain competitive in the long-term need solutions that are future-ready today.

Seamlessly-integrated-vial-fill-finish-line-from-Syntegon
Seamlessly integrated vial fill finish line from Syntegon

Vials are among the most commonly used packaging formats for highly innovative pharmaceuticals – and represent a significant economic opportunity for pharmaceutical manufacturers and CDMOs. They are under increasing pressure to deliver a wider range of products with differing characteristics, dosage forms, and batch sizes within ever shorter timeframes. This requires highly flexible lines that minimize overproduction and enable fast time-to-market – and allow pharmaceutical companies to adapt swiftly. But what exactly does flexibility mean in vial filling today and tomorrow, what are the key drivers, and how should the ideal vial filling line be designed?

A rapidly changing pharmaceutical landscape

Growth in the liquid vial market is driven by two trends. Large-scale drugs such as semaglutide and vaccines require high-speed, high-output fill-finish equipment, while many emerging biopharmaceuticals and antibody-drug conjugates (ADCs) are produced in small batches or even tailored for individual patients. Applications range from large formats for multi-dosage needs to small single-dose vials. Especially new complex products vary in viscosity, sensitivity, and other characteristics, demanding ever higher flexibility. At the same time, regulations set ever-higher standards for sterile fill-finish operations.

As a result, manufacturers – and especially CDMOs, whose role in fill-finish operations is set to grow over the coming years – increasingly seek equipment that combines high output with versatility and regulatory readiness. Shifting between batches of different volumes and complex products requires high operational flexibility. Modern fill-finish lines should be able to process several vial sizes on a single platform. Beyond format compatibility, reducing downtime through rapid, automated, tool-less changeovers and optimized cleaning is critical. A modular design adds scalability and allows the integration of components such as freeze-dryers or isolators without extensive system changes, securing long-term production efficiency.

What hinders fill-finish flexibility?

Vial filling under isolator conditions
Vial filling under isolator conditions

Despite the rising demand for adaptable production, many fill-finish lines still face bottlenecks that limit flexibility, including manual changeovers, inefficient cleaning, and non-standardized interfaces. Manual format changes extend downtime and increase the risk of human error, potentially causing delays or batch loss. Cleaning is another constraint: In aseptic processing, it must be thorough, validated, and well documented. Otherwise, it can become a significant source of downtime and administrative effort.

Non-standardized interfaces further restrict flexibility, as they hinder the fast integration of novel or newly required technologies such as freeze-dryers or barrier systems. The latter, for example, are now explicitly recommended by EU GMP Annex 1 to improve product safety by minimizing manual intervention. Hence, manufacturers will require at least restricted access barrier systems (RABS) for new product approvals, while new lines should include isolators by default. As demand for lyophilized products and higher containment grows, standardized interfaces will be critical. Without them, retrofits become slower, costlier, and hinder rapid capacity expansion, leaving manufacturers less able to meet evolving market needs.

From filling technologies to automation

Precision vial filling in progress
Precision vial filling in progress

To overcome these limitations, the focus should be on four key design principles. Firstly, meeting diverse demands – from sensitive biopharmaceuticals to high-volume products – requires flexible filling technologies. This means the ability to run multiple systems on one machine and change parts with minimal downtime. Both stainless steel multi-use and single-use solutions have their roles, while truly flexible lines can support various filling systems – from peristaltic, rolling diaphragm, and rotary valve piston pumps to mass-flow and time-pressure filling, with combi stations handling several systems simultaneously to save space and time.

Yet no matter the number of supported filling technologies, vial fill-finish lines can only deliver on their promise if changeovers are just as reliable. The most effective way to address this is through automated, tool-less changeovers. Compared to manual or semi-automated approaches, these systems are not only less error-prone, but also significantly faster. Gentle or even contactless transport of the vials is a good example of this principle. To truly unlock flexibility, however, automation must extend beyond the filling station. Each process step of the fill-finish line, from cleaning and sterilization to freeze-drying and stoppering, should enable fast, automated adaptation.

Integrated cleaning and seamless integration

Sealing machine securing caps on vials
Sealing machine securing caps on vials

Most changeovers require cleaning and sterilization, with few exceptions for single-use or non-contact parts. Optimizing these processes is a key lever to reducing downtime and enhancing line flexibility. Many modern vial fill-finish lines feature integrated CIP/SIP systems that automatically clean and sterilize equipment without disassembly, saving time and ensuring compliance across products. Since Annex 1 places particular emphasis on filter testing using PUPSIT (pre-use post-sterilization integrity testing), manufacturers should opt for integrated or easily integrable solutions to ensure maximum flexibility.

Finally, creating future-proof flexibility is best achieved with a modular vial filling line design and seamless integration possibilities. With rising regulatory demands, modularity is far more than a design choice – it is a long-term safeguard, enabling adaptability to new requirements. For example, a modular line with standardized interfaces allows containment upgrades even for systems originally built without barrier technology. Modularity and standardized interfaces also make it possible to add capabilities such as freeze-drying, giving pharmaceutical manufacturers and CDMOs the freedom to expand their product portfolio over time.

Ensuring future-proof vial fill-finish operations

Flexible vial filling lines are a strategic investment that delivers long-term value. They significantly increase equipment availability and overall efficiency, resulting in a higher return on investment. Production assets are better utilized, while pharmaceutical manufacturers and CDMOs can respond more dynamically to evolving market needs and regulatory shifts. But true flexibility goes beyond selecting the right equipment. It also requires a partner who understands the broader context of pharmaceutical production and can support customers throughout all process steps and across the entire machine lifecycle.

Choosing a strategic partner like Syntegon with a design philosophy that supports these goals and provides seamless processing equipment with flexibility at its heart is a key success factor. From formulation to filling and closing, sterilizing, freeze-drying, and inspection at any containment level, Syntegon offers seamlessly integrated, vial fill-finish lines. Moreover, spare parts, maintenance kits, and expert consulting make a real difference in daily operations. This way, pharmaceutical manufacturers and CDMOs are ready to meet today’s needs – and tomorrow’s opportunities.

 Author

Sarah Springer Syntegon
Sarah Springer
Global Product Manager -Vial, Ampoule, and Filling Systems
Syntegon Technology
sarah.springer@syntegon.com

Company: Syntegon Technology GmbH


Syntegon is a leading global technology company and strategic partner to the pharmaceutical, biotech, and food industries. With a strategic focus on the growing pharmaceutical and biotech sectors, the company plays a vital role in global healthcare, providing in-depth process expertise and mission-critical technologies for the safe, efficient, and compliant production of essential medicines. In the food sector, Syntegon is recognized for high-speed, high-precision packaging solutions, drawing on unique engineering excellence to help manufacturers improve performance and product quality. Its global service business supports about 75,000 installed systems with a comprehensive lifecycle offering, ensuring uptime, efficiency, and long-term value.

In fiscal year 2024, Syntegon generated 1.6 billion euros in sales. Headquartered in the Stuttgart region in Germany, the company employs 6,900 people at 47 locations in more than 20 countries. With over 160 years of industry expertise, ... Read more »

Send Enquiry for this story

By submitting this form you are giving a consent to Worldpharmatoday.com to store your submitted information.
See our Privacy Policy to learn more about how we use data.

Latest stories

Related stories

IoT-Enabled Packaging for Cold Chain Monitoring

IoT-Enabled Packaging Enhancing Cold Chain Monitoring The pharmaceutical industry has...

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »